The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

GSK Plc’s experimental drug helped prevent serious asthma attacks in two late-stage studies, easing the path forward for a ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic ...

British drugmaker GSK (GSK.L), opens new tab said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not ...

Meanwhile, the time has come to turn to our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. … Hims & Hers Health plans to sell compounded ...

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Specifically, on the key price-to-earnings ratio (P/E) measurement of relative stock valuation, it trades at just 16.7. This is at the bottom of the list of its peers ... is litigation over GSK’s ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in ...